IBM Signs $1.4 Billion Global Strategic Outsourcing Agreement With AstraZeneca
LONDON - 16 Jul 2007 - IBM (NYSE: IBM) today announced that they have signed a $1.4 billion, seven-year global strategic outsourcing agreement with AstraZeneca. The agreement renews and expands on the scope of an existing contract and covers the provision of IT infrastructure services to 60 countries. It includes services to additional functions within AstraZeneca, one of the world’s largest pharmaceutical companies.
In the terms of the agreement, IBM will provide a single global technical infrastructure, managing IT services for AstraZeneca across its global organisation. This includes server and storage hosting, service desks, PC management, network and communications services, including e-mail, and computer operations support. AstraZeneca will retain control of its overall IT strategy and the development and support of its application systems.
Richard Williams, Chief Information Officer of AstraZeneca, said, “This innovative agreement with IBM will enable AstraZeneca to deliver greater value to the business by providing consistent infrastructure services globally, enabling a faster and more efficient rollout of new technology, with improved levels of service. Leveraging IBM’s global delivery capabilities and economies of scale, will allow AstraZeneca to focus its efforts on adding value to its scientific, commercial and supply operations, thereby helping the Company to deliver more medicines that make a meaningful difference to patients. In allowing IBM greater autonomy on methods of delivery, the agreement will result in cost efficiencies when compared with running in-house systems.”
“IBM will marshal its global resources to provide a flexible and agile infrastructure enabling AstraZeneca to continue implementing its plans to grow and lead in the pharmaceutical industry,” said Doug Elix, Senior Vice President, IBM. “The trust we have built over the past seven years will help IBM and AstraZeneca break new ground in transformational services in the next seven.”
The agreement was signed in July 2007.
For more information on IBM, visit www.ibm.com.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.
- Contact Information
- Adam Emery
- IBM Media Relations
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.